Summit Therapeutics (SMMT) Gains from Investment Securities (2019 - 2026)

Summit Therapeutics has reported Gains from Investment Securities for 8 years, with the latest figure at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 27.7% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $16.7 million (up 106.2% YoY), and the FY2025 full-year result was $17.1 million, up 304.55% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $1.0 million, down from $16.2 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $16.2 million in Q4 2025, with the low at -$2.9 million in Q3 2025.
• Historically, Gains from Investment Securities has averaged $2.7 million across 5 years, with a median of $1.8 million in 2025.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities slumped 317.87% — and 2025, when it soared 158.01%.
• Summit Therapeutics' Gains from Investment Securities stood at -$2.8 million in 2022, then soared by 254.03% to $4.2 million in 2023, then jumped by 56.94% to $6.7 million in 2024, then soared by 143.79% to $16.2 million in 2025, then sank by 93.68% to $1.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.0 million (Q1 2026), $16.2 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.